Tirzepatide side effects: what TikTok gets right and wrong

What did @heyitsmaraj actually say?

Marjana describes starting tirzepatide at the lowest available dose and experiencing intense, widespread muscle soreness beginning roughly 12 hours after her first injection. She says the pain ran "from the side of my neck all the way down my back, lower back, back of my thighs" and felt like a sunburn under the skin combined with being "run over by a truck." It lasted about 36 hours. She also speculates that her Hashimoto's disease may have made her react differently. This is a first-person symptom report, not a medical claim about mechanism or treatment.

To her credit, she read the prescribing literature, acknowledged the known GI and dizziness side effects, and was genuinely surprised this one wasn't mentioned there. That's fair. It isn't listed as a common adverse event in the FDA label for Zepbound or Mounjaro.

Does the science back this up?

Scattered but real. Myalgia, meaning generalized muscle pain, does appear in post-market surveillance and patient forums for GLP-1 receptor agonists, though it is not a commonly reported adverse event in the pivotal trials. The SURPASS and SURMOUNT trial series for tirzepatide reported nausea, vomiting, diarrhea, and injection-site reactions as the dominant side effects. Muscle pain wasn't a headline finding.

However, GLP-1 receptors are expressed in muscle tissue, and some researchers have hypothesized that early immune or inflammatory responses after injection could contribute to transient myalgia. A 2023 case series published in Obesity (Almandoz et al.) documented musculoskeletal complaints in patients initiating GLP-1 agonists, though causality wasn't firmly established. The symptom pattern Marjana describes, sudden onset, posterior distribution, resolving in 24 to 48 hours, is consistent with what's being discussed informally in clinical practice. It's plausible. It's just not well-studied yet.

What did they get wrong (or right)?

She got more right than wrong. The symptom she describes is genuinely underreported in patient-facing materials, and her instinct to track injection site, timing, and symptom duration is exactly what good self-monitoring looks like. Changing injection sites to see if symptoms shift is also reasonable and aligns with standard guidance on rotation.

Where she steps onto shakier ground is the Hashimoto's speculation. She says someone suggested that "people with autoimmune diseases react differently." That's not an unreasonable hypothesis, but there's no published clinical data specifically linking Hashimoto's thyroiditis to increased myalgia risk on tirzepatide. Hashimoto's is common, particularly in women, and the overlap with this patient population is large enough that correlation could easily be confused for causation. She frames it as a possibility rather than a fact, which is the right epistemic posture, but 99,000 viewers may not absorb that nuance.

She also refers to the medication as a "GLP-1" throughout, which is a common shorthand but slightly inaccurate. Tirzepatide is a dual GIP and GLP-1 receptor agonist. That distinction may matter clinically when comparing side effect profiles across agents.

What should you actually know?

If you start tirzepatide or another GLP-1 class medication and experience diffuse muscle soreness within 12 to 24 hours of injection, you are not alone and you are not imagining it. But "other people on TikTok had it too" is not a substitute for telling your prescriber. Widespread myalgia can also indicate injection-site infection, immune reactions, or, in rare cases, drug-induced myositis, a more serious condition worth ruling out.

The FDA label for tirzepatide does not list generalized myalgia as a common adverse event, which means your provider may not proactively warn you about it. That's a gap worth closing in the clinical conversation before you start, not after your first painful night on the couch. If symptoms persist beyond 48 hours, worsen, or are accompanied by dark urine or fever, contact your prescriber. Those features could point toward rhabdomyolysis, which is rare but documented with other injectable medications.

Finally, the 2.5 mg starting dose she mentions is the approved initiation dose, and her plan to stay at that level while her body adjusts is clinically sensible. That is not a recommendation to follow her exact approach. Your prescriber sets your dose.

The bottom line

Marjana's experience is credible, her reporting is careful, and she's describing a real gap in patient education around tirzepatide. The science doesn't fully confirm or deny a causal link yet. What's clear is that widespread myalgia after GLP-1 class injections is being reported often enough that clinicians should be asking about it and patients should know to mention it.